DrugPatentWatch Database Preview
Drugs in Development Information for Gefapixant
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug Gefapixant?
Gefapixant is an investigational drug.
There have been 10 clinical trials for Gefapixant.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 14th 2020.
The most common disease conditions in clinical trials are Cough, Common Cold, and Urinary Incontinence, Stress. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Afferent Pharmaceuticals, Inc., and [disabled in preview].
There are fourteen US patents protecting this investigational drug and one hundred and twenty international patents.
Summary for Gefapixant
| US Patents | 14 |
| International Patents | 120 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-01-14) |
| Vendors | 14 |
Recent Clinical Trials for Gefapixant
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) | Merck Sharp & Dohme Corp. | Phase 3 |
| Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) | Merck Sharp & Dohme Corp. | Phase 3 |
| A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) | Merck Sharp & Dohme Corp. | Phase 3 |
Clinical Trial Summary for Gefapixant
Top disease conditions for Gefapixant
Top clinical trial sponsors for Gefapixant
US Patents for Gefapixant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gefapixant | Start Trial | Methods and compositions for treating diseases and conditions | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | Start Trial |
| Gefapixant | Start Trial | Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | Start Trial |
| Gefapixant | Start Trial | Diaminopyrimidines as P2X.sub.3 and P2X.sub.2/3 antagonists | Roche Palo Alto LLC (Palo Alto, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gefapixant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gefapixant | European Patent Office | 3164132 | 2034-07-03 | Start Trial |
| Gefapixant | World Intellectual Property Organization (WIPO) | 2016004358 | 2034-07-03 | Start Trial |
| Gefapixant | Australia | 2014308606 | 2033-08-23 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
